Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities

American Journal of Physiology - Endocrinology and Metabolism

Volumn 278, Issue 6 41-6, 2000, Pages

  Baxter, Robert C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Cancer cell growth; Structural determinants; Type I insulin like growth factor receptor

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR;

BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CELL GROWTH; ENZYME ACTIVITY; GROWTH REGULATION; HUMAN; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS;

EID: 0033920612     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2000.278.6.e967     Document Type: Review

References (100)

1. Andress DL. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol Endocrinol Metab 274: E744-E750, 1998.
2. Andress DL, Loop SM, Zapf J, and Kiefer MC. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem Biophys Res Commun 195: 25-30, 1993.
3. Bach LA, Hsieh S, Brown AL, and Rechler MM. Recombinant human insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts. Endocrinology 135: 2168-2176, 1994.
4. Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, and Rechler MM. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem 268: 9246-9254, 1993.
5. Bach LA, Thotakura NR, and Rechler MM. Human insulin-like growth factor binding protein-6 is O-glycosylated. Biochem Biophys Res Commun 186: 301-307, 1992.
6. Ballard J, Baxter R, Binoux M, Clemmons D, Drop S, Hall K, Hintz R, Rechler M, Rutanen E, and Schwander J. On the nomenclature of the IGF binding proteins. Acta Endocrinol 121: 751-752, 1989.
7. Baxter RC. Molecular aspects of insulin-like growth factor binding proteins. Adv Mol Cell Endocrinol 1: 123-159, 1997.
8. Baxter RC, Binoux MA, Clemmons DR, Conover CA, Drop SLS, Holly JMP, Mohan S, Oh Y, and Rosenfeld RG. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. J Clin Endocrinol Metab 83: 3213, 1998.
9. Baxter RC and Skriver L. Altered ligand specificity of proteolysed insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 196: 1267-1273, 1993.
10. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, and Bierich JR. Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 125: 766-772, 1989.
11. Blundell TL, Bedarkar S, Rinderknecht E, and Humbel RE. Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding. Proc Natl Acad Sci USA 75: 180-184, 1978.
12. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EEO, Weiler J, and Bar RS. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5: 1-17, 1995.
13. Bramani S, Song H, Beattie J, Tonner E, Flint DJ, and Allan GJ. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I. J Mol Endocrinol 23: 117-123, 1999.
14. Brinkman A, Kortleve DJ, Schuller AGP, Zwarthoff EC, and Drop S. Site-directed mutagenesis of the N-terminal region of IGF binding protein-1: analysis of IGF binding capability. FEBS Lett 291: 264-268, 1991.
15. Brinkman A, Kortleve DJ, Zwarthoff EC, and Drop SL. Mutations in the C-terminal part of insulin-like growth factor (IGF)-binding protein-1 result in dimer formation and loss of IGF binding capacity. Mol Endocrinol 5: 987-994, 1991.
16. Buckbinder L, Talbott R, Velasco MS, Takenaka I, Faha B, Seizinger BR, and Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995.
17. Busby WJ, Klapper DG, and Clemmons DR. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions. J Biol Chem 263: 14203-14210, 1988.
18. Campbell PG and Andress DL. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation by IGFBP-5-(201-218). Am J Physiol Endocrinol Metab 273: E996-E1004, 1997.
19. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, and Powell DR. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol Endocrinol Metab 275: E321-E331, 1998.
20. Carr JM, Grant PA, Francis GL, Owens JA, Wallace JC, and Walton PE. Isolation and characterization of ovine IGFBP-4: protein purification and cDNA sequence. J Mol Endocrinol 13: 219-236, 1994.
21. Ceda GP, Fielder PJ, Henzel WJ, Louie A, Donovan SM, Hoffman AR, and Rosenfeld RG. Differential effects of insulin-like growth factor (IGF)-I and IGF-II on the expression of IGF binding proteins (IGFBPs) in a rat neuroblastoma cell line: isolation and characterization of two forms of IGFBP-4. Endocrinology 128: 2815-2824, 1991.
22. Chen J-C, Shao Z-M, Sheikh MS, Hussain A, LeRoith D, Roberts CT, and Fontana JA. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 158: 69-78, 1994.
23. Cheung PT, Smith EP, Shimasaki S, Ling N, and Chernausek SD. Characterization of an insulin-like growth factor binding protein (IGFBP-4) produced by the B104 rat neuronal cell line: chemical and biological properties and differential synthesis by sublines. Endocrinology 129: 1006-1015, 1991.
24. Clark RG, Mortensen D, Reifsynder D, Mohler M, Etcheverry T, and Mukku V. Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycemic and growth promoting activities of rhIGF-I in the rat. Growth Regul 3: 50-52, 1993.
25. Clemmons DR, Cascieri MA, Camacho-Hübner C, McCusker RH, and Bayne ML. Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity. J Biol Chem 265: 12210-12216, 1990.
26. Conover CA. Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3. Endocrinology 129: 3259-3268, 1991.
27. Conover CA, Clarkson JT, and Bale LK. Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Endocrinology 137: 2286-2292, 1996.
28. Conover CA, Durham SK, Zapf J, Masiarz FR, and Kiefer MC. Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants. J Biol Chem 270: 4395-4400, 1995.
29. Conover CA, Perry JE, and Tindall DJ. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. Endocrinology 80: 987-993, 1995.
30. Cooke RM, Harvey TS, and Campbell ID. Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study. Biochemistry 30: 5484-5491, 1991.
31. Coverley JA and Baxter RC. Regulation of insulin-like growth factor (IGF) binding protein-3 phosphorylation by IGF-I. Endocrinology 136: 5778-5781, 1995.
32. Cox GN, McDermott MJ, Merkel E, Stroh CA, Ko SC, Squires CH, Gleason TM, and Russell D. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology 135: 1913-1920, 1994.
33. De Mellow JS and Baxter RC. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 156: 199-204, 1988.
34. Dubaquie Y and Lowman HB. Total alanine-scanning mutagenesis of insulin-like growth factor I (IGF-I) identifies differential binding epitopes for IGFBP-I and IGFBP-3. Biochemistry 38: 6386-6396, 1999.
35. Ernst M and Rodan GA. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 127: 807-814, 1990.
36. Fielder PJ, Pham H, Adashi EY, and Rosenfeld RG. Insulin-like growth factors (IGFs) block FSH-induced proteolysis of IGF-binding protein-5 (BP-5) in cultured rat granulosa cells. Endocrinology 133: 415-418, 1993.
37. Firth SM and Baxter RC. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol 160: 379-387, 1999.
38. Firth SM, Ganeshprasad U, and Baxter RC. Structural determinants of ligand and cell-surface binding of insulin-like growth factor-binding protein-3. J Biol Chem 273: 2631-2638, 1998.
39. Forbes B, Szabo L, Baxter RC, Ballard FJ, and Wallace JC. Classification of the insulin-like growth factor binding proteins into three distinct categories according to their binding specificities. Biochem Biophys Res Commun 157: 196-202, 1988.
40. Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, and Wallace JC. Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain. J Biol Chem 273: 4647-4652, 1998.
41. Francis GL, Aplin SE, McNeil KA, Milner SJ, Forbes BE, Ross M, Ballard FJ, and Wallace JC. Molecular interactions of IGF-I and IGF-II with their binding proteins and receptors. In: The Insulin-Like Growth Factors and Their Regulatory Proteins, edited by RC Baxter, PD Gluckman, and RG Rosenfeld. Amsterdam: Elsevier, 1994, p. 57-66.
42. Francis GL, Upton FM, Ballard FJ, McNeil KA, and Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J 251: 95-103, 1988.
43. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, and Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19: 3278-3288, 1999.
44. Frystyk J, Grøfte T, Skjærbæk C, and Ørskov H. The effect of oral glucose on serum free insulin-like growth factor-I and -II in healthy adults. J Clin Endocrinol Metab 82: 3124-3127, 1997.
45. Gill ZP, Perks CM, Newcomb PV, and Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 272: 25602-25607, 1997.
46. Hamon GA, Hunt TK, and Spencer EM. In vivo effects of systemic insulin-like growth factor-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds. Growth Regul 3: 53-56, 1993.
47. Ho PJ and Baxter RC. Characterization of truncated insulin-like growth factor-binding protein-2 in human milk. Endocrinology 138: 3811-3818, 1997.
48. Hobba GD, Lothgren A, Holmberg E, Forbes BE, Francis GL, and Wallace JC. Alanine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding. J Biol Chem 273: 19691-19698, 1998.
49. Hoeck WG and Mukku VR. Identification of the major sites of phosphorylation in IGF binding protein-3. J Cell Biochem 56: 262-273, 1994.
50. Hoflich A, Lahm H, Blum W, Kolb H, and Wolf E. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 434: 329-334, 1998.
51. Hwa V, Oh Y, and Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Rev 20: 761-787, 1999.
52. Imai Y, Busby WH, Smith CE, Clarke JB, Garmong AJ, Horwitz GD, Rees C, and Clemmons DR. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J Clin Invest 100: 2596-2605, 1997.
53. Imai Y, Morales A, Clarke JB, Busby W, Fielder P, and Clemmons DR. Synthesis and characterization of IGFBP-5 and IGFBP-3 mutants that have no affinity for IGF-I (Abstract). GH and IGF Res 9: 372, 1999.
54. Irving JA and Lala PK. Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGF-beta, IGF-II, and IGFBP-1. Exp Cell Res 217: 419-427, 1995.
55. Iwashita M, Kudo Y, Yoshimura Y, Adachi T, Katayama E, and Takeda Y. Physiological role of insulin-like-growth-factor-binding protein-4 in human folliculogenesis. Horm Res 46, Suppl 1: 31-36, 1996.
56. Jones JI, D'Ercole AJ, Camacho HC, and Clemmons DR. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA 88: 7481-7485, 1991.
57. Jones JI, Gockerman A, Busby WH, Camacho-Hübner C, and Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 121: 679-687, 1993.
58. Jones JI, Gockerman A, Busby WJ, Wright G, and Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90: 10553-10557, 1993.
59. Kalus W, Zweckstetter M, Renner C, Sanchez Y, Georgescu J, Grol M, Demuth D, Schumacher R, Dony C, Lang K, and Holak TA. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 17: 6558-6572, 1998.
60. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, and Sharoni Y. Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem 272: 16514-16520, 1997.
61. Kratz G, Lake M, and Gidlund M. Insulin-like growth factor-1 and -2 and their role in the re-epithelialisation of wounds: interactions with insulin like growth factor binding protein type 1. Scand J Plast Reconstr Hand Surg 28: 107-112, 1994.
62. Lalou C, Lassarre C, and Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137: 3206-3212, 1996.
63. Lassarre C and Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 134: 1254-1262, 1994.
64. Leal S, Liu Q, Huang S, and Huang J. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272: 20572-20576, 1997.
65. Leal SM, Huang SS, and Huang JS. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-β receptor in mink lung-epithelial cells. J Biol Chem 274: 6711-6717, 1999.
66. Lewitt MS, Denyer GS, Cooney GJ, and Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129: 2254-2256, 1991.
67. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, and Keller G-A. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 138: 1763-1766, 1997.
68. Martin JL and Baxter RC. IGF binding proteins as modulators of IGF action. In: The IGF System, Molecular Biology, Physiology and Clinical Applications, edited by R Rosenfeld and C Roberts. Totowa, NJ: Humana, 1999, p. 227-255.
69. Martin JL and Baxter RC. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells. J Biol Chem 274: 16407-16411, 1999.
70. Martin JL, Coverley JA, Pattison ST, and Baxter RC. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136: 1219-1226, 1995.
71. McCusker RH and Clemmons DR. Use of lanthanum to accurately quantify insulin-like growth factor binding to proteins on cell surfaces. J Cell Biochem 66: 256-267, 1997.
72. Menouny M, Binoux M, and Babajko S. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity. Int J Cancer 77: 874-879, 1998.
73. Mohseni-Zadeh S and Binoux M. Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology 138: 5645-5648, 1997.
74. Murphy LJ. Insulin-like growth factor binding proteins: functional diversity or redundancy? J Mol Endocrinol 21: 97-107, 1998.
75. Nam TJ, Busby W, and Clemmons DR. Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology 138: 2972-2978, 1997.
76. O'Grady P, Liu Q, Huang SS, and Huang JS. Transforming growth factor beta (TGF-beta) type V receptor has a TGF-beta-stimulated serine/threonine-specific autophosphorylation activity. J Biol Chem 267: 21033-21037, 1992.
77. Oh Y, Muller H, Pham H, and Rosenfeld R. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268: 26045-26058, 1993.
78. Perks CM, Newcomb PV, Norman MR, and Holly JM. Effect of insulin-like growth factor binding protein-1 on integrin signaling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 22: 141-150, 1999.
79. Peterkofsky B, Gosiewska A, Wilson S, and Kim Y-R. Phosphorylation of rat insulin-like growth factor binding protein-1 does not affect its biological properties. Arch Biochem Biophys 357: 101-110, 1998.
80. Qin X, Strong DD, Baylink DJ, and Mohan S. Structure-function analysis of the human insulin-like growth factor binding protein-4. J Biol Chem 273: 23509-23516, 1998.
81. Rajah R, Valentinis B, and Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 272: 12181-12188, 1997.
82. Rechler MM and Clemmons DR. Regulatory actions of insulin-like growth factor-binding proteins. Trends Endocrinol Metab 9: 176-183, 1998.
83. Richman C, Baylink DJ, Lang K, Dony C, and Mohan S. Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology 140: 4699-4705, 1999.
84. Russo VC, Bach LA, Fosang AJ, Baker NL, and Werther GA. Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 138: 4858-4867, 1997.
85. Salahifar H, Baxter RC, and Martin JL. Insulin-like growth factor (IGF) binding protein-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology 138: 1683-1690, 1997.
86. Sara V, Carlsson-Skwirut C, Andersson C, Hall E, Sjogren B, Holmgren A, and Jornvall H. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA 83: 4904-4907, 1986.
87. Schedlich LJ, Young TF, Firth SM, and Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-S and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 273: 18347-18352, 1998.
88. Sommer A, Maack CA, Spratt SK, Mascarenhas D, Tressel TJ, Rhodes ET, Lee R, Roumas M, Tatsuno GP, Flynn JA, Gerber N, Taylor J, Cudny H, Nanney L, Hunt TK, and Spencer EM. Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3. In: Modern Concepts of Insulin-Like Growth Factors, edited by EM Spencer. New York: Elsevier, 1991, p. 715-728.
89. Suikkari A-M, and Baxter RC. Insulin-like growth factor binding protein-3 is functionally normal in pregnancy serum. J Clin Endocrinol Metab 74: 177-183, 1992.
90. Terasawa H, Kohda D, Hatanaka H, Nagata K, Higashihashi N, Fujiwara H, Sakano K, and Inagaki F. Solution structure of human insulin-like growth factor II; recognition sites for receptors and binding proteins. EMBO J 13: 5590-5597, 1994.
91. Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, and Fowlkes JL. Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136: 3527-3533, 1995.
92. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, and Ballard FJ. Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects. Biochem J 291: 781-786, 1993.
93. Twigg SM, Kiefer MC, Zapf J, and Baxter RC. Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit: role of the carboxyl-terminal domain. J Biol Chem 273: 28791-28798, 1998.
94. Valentinis B, Bhala A, DeAngelis T, Baserga R, and Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9: 361-367, 1995.
95. Villaudy J, Delbé J, Blat C, Desauty G, Golde A, and Harel L. An IGF binding protein is an inhibitor of FGF stimulation. J Cell Physiol 149: 492-496, 1991.
96. Vorwerk P, Yamanaka Y, Spagnoli A, Oh Y, and Rosenfeld RG. Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine. J Clin Endocrinol Metab 83: 1392-1395, 1998.
97. Wang J-F, Hampton B, Mehlman T, Burgess WH, and Rechler MM. Isolation of a biologically active fragment from the carboxy terminus of the fetal rat binding protein for insulin-like growth factors. Biochem Biophys Res Commun 157: 718-726, 1988.
98. Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A, and White A. Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. J Clin Endocrinol Metab 80: 3520-3527, 1995.
99. Yamanaka Y, Fowlkes J, Wilson E, Rosenfeld R, and Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140: 1319-1328, 1999.
100. Zadeh SM and Binoux M. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type I IGF receptor gene. Endocrinology 138: 3069-3072, 1997.